Neuren adds SYNGAP1-related disorder to NNZ-2591 pipeline
Filed with ASX · · 2 pages · English
Summary by 6ix AI
This disorder currently has no approved treatments and is caused by a genetic variant affecting neuronal communication. The company is focused on developing therapies for serious neurological disorders with limited treatment options.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Neuren Pharmaceuticals Limited on 6ix
Earlier from Neuren Pharmaceuticals
- DAYBUE Q2 2025 net sales US$96.1 million up 14% from Q2 2024
- US patent allowed for NNZ-2591 to treat Pitt Hopkins
- AGM Chair Address & CEO Presentation
- DAYBUE Q1 2025 net sales US$84.6m up 11% from Q1 2024
- NEU confirms primary endpoints for Phase 3 trial in PMS
Later from Neuren Pharmaceuticals
- First site initiated for Neuren's PMS Phase 3 trial
- Half Yearly Report and Accounts
- Fast Track granted by FDA for NNZ-2591 in Phelan-McDermid
- Record DAYBUE net sales of US$101.1 million in Q3 2025
- FDA approves DAYBUE STIX (trofinetide), powder formulation
Follow Neuren Pharmaceuticals into a list and get an email when it puts out news.
Follow Neuren Pharmaceuticals